The glycoprotein (Gp) IIb/IIIa is a platelet membranebound receptor involved in the final stage of the platelet aggregation process. It plays a central role in the binding of fibrinogen (Fbg) during normal hemostasis and arterial thrombosis. [1] [2] [3] Recently, development of receptor antagonists has been an area of active research in many pharmaceutical companies in the quest for a new type of orally active low molecular weight anti-aggregation agent. [4] [5] [6] [7] [8] [9] [10] [11] [12] In the previous report, 13) we described our strategy for the development of naphthalene compounds as GP IIb/IIIa antagonists. Recently, Gp IIb/IIIa antagonists with bicyclic 5-amidinoindoles have been reported by Su and co-workers.
11)
The 10-fold difference in potency observed between indole and acyclic compounds suggested a conformational restriction in the indole part or a CH-p interaction effect in that region of the receptor. However, our acyclic compound 2 ( Fig.  1 ) possessed similar inhibitory activity to the naphthalene 1. This potency suggests that the condensed heterocycle does not provide an additional CH-p interaction effect compared with an acyclic compound within that region of Gp IIb/IIIa. Our previous structure-activity relationship and molecular modeling studies of these naphthalene compounds combined with conformational studies established the importance of geometrical parameters and of the three-point interaction between amide hydrogen bonds, the amidinoaryl moiety, and the carboxylic acid moiety. Carboxylic acid derivative 1 was found to be a potent antagonist of Fbg receptors. In designing our antagonists, we postulated that the affinity of binding to the Fbg receptor is dependent on the geometrical relationship between the carboxylic acid and the amidino group, and we designed the condensed heterocyclic analogues to improve this geometrical relationship. These studies led to the identification of 1 as a lead compound. 13) In this paper, as shown in Fig. 1 , we describe the synthesis, structure-activity relationship, and in vitro and ex vivo activities of this novel series of condensed heterocyclic compounds with naphthalene compound 1 as lead compound. 17e, 17f and a number of other compounds with a cyclohexane unit also have enhanced activity. These compounds are highly selective compared with other RGD-recognizing integrins and demonstrate a wide-ranging potent inhibition toward major aggregation agonists. The corresponding prodrugs, ethyl trans-4-(5-amidinobenzofuran-2-carboxamido)-cyclohexyloxyacetate 18e and ethyl trans-3-[4-(5-amidinobenzofuran-2-carboxamido)cyclohexyl]propionate 18f, are a potent fibrinogen receptor antagonists with a long duration of action after oral administration.
Chemistry Our compounds can be structurally divided into two parts, a basic part (amidinoaryl moiety) and an acidic part (carboxylic acid moiety) (Fig. 1) . Preparation of the target compounds used to investigate the effects of the basic part, listed in Table 1 , is illustrated in Charts 1 and 2. The cyano acids 3 were prepared from the nitro ester by reduction (e.g. hydrogenation), the Sandmeyer reaction and basic hydrolysis. The 6-cyanoindole-2-carboxylic acid 3c was prepared using Fisher's indolization. 14) Compound 3d was obtained by N-alkylation from 3c, 15) and 3h was prepared from 2-acetyl-4-nitrophenol in four steps according to the procedure for the preparation of 3a. The amino ester 4 was prepared as reported in the previous paper.
The preparation of 7a-h is shown in Chart 1. Coupling of the aromatic amino ester 4 with each of the cyano acids 3a, 3c, 15) 3d-g led to the corresponding intermediates. The amide bonds were prepared using standard coupling reagents, e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDI) and diisopropylcarbodiimide.
A known three-step sequence route 16) (thioimidate is formed by first treating the cyano group with hydrogen sulfide followed by alkylation with methyl iodide; next, treatment of the methylthioimidate with ammonium acetate affords the amidine group as the hydriodide salt) was used to convert the cyano group to the amidino group. Deprotection of the tert-butyl esters using trifluoroacetic acid (TFA) afforded the target compound in pure form. In 7b, nitrile 8b 15) was converted to the corresponding amidine by the Pinner reaction, 17) and basic hydrolysis of ester 9 afforded the carboxylic acid 10. Condensation with 4 led to the amidino ester 11. Basic hydrolysis of the ester afforded target compound 7b (Chart 2). However, during the preparation of 4-(5-amidino-1H-indole-2-carboxamide)phenoxyacetic acid, conversion of the nitrile to the corresponding product failed using hydrogen sulfide, and starting nitrile was recovered.
Next, the acidic part was modified. Preparation of the target compounds used to investigate the effect of the acidic part in Tables 4-6 is illustrated in Charts 3-6. The acidic part can be prepared from commercially available starting materials using known methods. Firstly, the acidic part of 7a was replaced with various carboxylic acids containing an extra ring as shown in Tables 4 and 5 . The reactions of 3a, 3h, 3i (a: YϭH, h: YϭMe, i: YϭOMe) with the various acidic derivatives 12a-d, h, l and m offered 13a-d, h, l and m in yields ranging from 38-100%. The cyano group Fig. 1 . Progression from Naphthalene compound 1 to Condensed Heterocycles of 13 was converted to the corresponding amidino group by a known three-step route with H 2 S. 17) In other cases, the Pinner reaction 18) (33%-quantitatively yield) was also used to obtain the amidino derivatives. Cleavage of the tert-butyl ester using TFA or saponification of the ethyl ester using sodium hydroxide afforded the acids in 29-91% yield after purification (Chart 3).
Chart 4 illustrates the preparation of 17e, f, g, i, j and k. The key intermediate 19 was easily prepared by the procedure described above. The cyano group of 3a was converted to the imidate by the Pinner reaction using saturated HClEtOH. Treatment of the imidate with ammonia in ethanol afforded the amidine. The amidino group was protected as the benzyloxycarbonyl (Z) derivative. The reaction of 19 with the various acidic derivatives 12e, f, g, i, j and k gave 20e, f, g, i, j and k in 21-94% yield. The amide bonds were prepared using EDI-1-hydroxy-1H-benzotriazole (HOBt). Deprotection of Z-protection via hydrogenation using 10% palladium on charcoal and cleavage of the tert-butyl esters using TFA or saponification of the ethyl ester using sodium hydroxide afforded the desired product 17e, f, g, i, j and k in 35-95% yield in analytically pure form. Furopyridines 29e and 29f were prepared using the same method (total yield 12-27%) (Chart 5).
Finally, to examine the effects of various condensed heterocycle systems on antagonist activities, a series of derivatives (27e, 28d, e, 29d) was prepared from the acidic derivative 12e and the corresponding 3c, 3f and 3g, using the method outlined above, with a total yield of 7-37%. The esters 30e and 31e were prepared from acids 27e and 28e (Chart 6).
Results and Discussion
In the process of the design of our antagonists, we postulated that the affinity of binding to the Fbg receptor is dependent on the geometrical relationship between the carboxylic acid and the amidino group, and we designed a condensed heterocyclic analogues to improve this geometry. Firstly, modification of 1 as a lead compound involved the basic part. Table 1 shows the synthesized amidino-condensed heterocyclic compounds with their IC 50 values for inhibition of ADP-induced aggregation of human platelet-rich plasma (PRP).
18) The 5-amidinobenzofuran 7a and 6-amidinoindole 7c possessed similar activity to the parent compound 1, Ro43-8857, and BIBU-52. The 6-amidinobenzothiophene 7f was approximately four-fold more potent than 1 in the platelet aggregation assay. On the other hand, the 6-amidinobenzofuran 7b and 5-benzothiophene 7e were one order less active than 1. Replacement of the benzofuran ring in 7a with a furo [2, 3-b] pyridine ring afforded 7g, which was a potent inhibitor. 7h, formed by 3-methyl substitution on the benzofuran ring of derivative 7a, showed similar inhibitory activity to the latter. Addition of an N-methyl group to the indole 7d reduced the activity four-fold compared with the corresponding 7c. As a result, the 5-amidinobenzofuran, 6-amidinoindole, 6-amidinobenzothiophene, and 5-amidinofuro [2, 3-b] pyridine were selected as the basic part.
Nafamostat, a serine protease inhibitor with an amidinonaphthol unit, was selected as our lead compound for the development of Gp IIb/IIIa antagonists. These drugs act on blood clotting disorders by suppressing clotting proteases, including thrombin. As a side-effect, they sometimes prolong the bleeding time. The specificity of the condensed heterocyclic compounds for inhibition of a variety of serine proteases was evaluated by measuring the apparent inhibition constant (Ki app ). 19) As shown in Table 2 , compound 7c has lost its ability to inhibit these proteases.
7a displayed potent inhibition of human platelet aggregation. However, lead compound 1, 7a and its prodrug showed low oral potency in a guinea pig model (Table 3) . We attempted to improve the oral potency of these compounds by modifying their physical properties.
Lilly researches have used alkyl chains as the acidic part of Gp IIb/IIIa antagonists. 11) Compound 7a, which possesses a phenyl ring in the acidic part, was more potent than alkyl chain compounds. We assume that this difference of activity may be due to a steric conformational restriction and to a more appropriate positioning of the pharmacophore. Our approach involved modifying the aromatic ring (Table  4 ). The N-methyl amide compound 17a, in which the Nmethyl was incorporated into 7a, showed weak activity. When the phenoxy group was replaced by pyridine and the series of phenyl-substituted analogues, these analogues were not significantly different in potency from the phenoxy analogue 17a. The next strategy, as shown in Fig. 1 , was to design molecules with the acidic part removed to construct a new skeleton, modified to enhance the activity and oral potency (Table 5) . These compunds (17e-k) showed IC 50 values of 6-70 nM in human PRP with the exception of 17h. The potency was markedly decreased in 17h which had an IC 50 Ͼ5 mM. The introduction of a methyl or methoxy group in the 3-position of benzofuran led to compounds 17l and 17m, respectively. It is interesting to note that the inhibitory potency against the receptors was 0.027 mM for 17l and 0.13 mM for 17m. 17m was, thus, approximately five-fold less potent than 17l and parent compound 7a. Bulky substitution may lead to a decrease in antiaggregatory activity, since the methoxy substitution was bulkier than the methyl substitution. This finding indicates, interestingly, that the spatial restriction of this position through introduction of a functional group leads to a change in antiaggregatory activity, and/or that incorporation of a hydrogen bond-accepting group (MeO), as in 17m, is unsuccessful.
When the benzofuran was replaced by an alternative condensed heterocycle (as shown in Table 6 ), the resulting analogues (27e, 28d, 28e, 29d, 29e, 29f) displayed similar inhibitory activity (IC 50 ϭ0.01-0.03 mM). This result suggested that the basic part was exchangeable with 6-amidinoindole, 6-amidinobenzothiophen, and 5-amidinofuro [2, 3-b] pyridine. Since 17e, 27e, and 28e were not soluble in water, esterification of 17e, 27e, and 28e provided the corresponding ethyl esters 18e, 30e, and 31e as prodrugs and these were soluble in water. The effect of 18e, 30e, and 31e at 1 mg/kg i.v. on ex vivo ADP (1 mM)-induced whole blood platelet aggregation in anesthetized guinea pigs is shown in Fig. 2 . The platelet aggregation response of 30e and 31e was 60% or less inhibition within 30 min. These results indicate that benzofuran derivatives produce long lasting of action following i.v. administration and slow metabolism and/or excretion from blood. Furthermore, the in vitro and ex vivo activities of compounds 17e and 17f were evaluated.
In a study of the antiaggregatory potency of 17e and 17f, inhibition of the binding of [
125 I] Fbg 20) to activated human platelets gave IC 50 values of 0.011 and 0.003 mM, respectively (Table 7) , approximately three orders of magnitude more potent than RGDS (IC 50 ϭ60 mM). 17e and 17f were found to antagonize Gp IIb/IIIa very strongly.
An interesting feature of those compounds was that the inhibition of platelet aggregation in rabbit was similar, in terms of IC 50 value, to that in human, dog and guinea pig in vitro (Table 8 ). Most non-peptide Gp IIb/IIIa antagonists (SC-54701, Ro43-8857 and BIBU-52 etc.) have only a weak effect on rabbit platelets. The distances are summarized in Table 9 . The distance between the carbon (C 1 ) of the amidino or guanidino group and the carbon (C 2 ) of the carbonyl group was C 1 -C 2 . The distance between the carbon (C 1 ) of the amidino or guanidino group and the hetero atom, which can interact with the receptor, was C 1 -(hetero atom). The distance between the carbon (C 2 ) of the carbonyl group and the hetero atom, which can interact with the receptor, was (hetero atom)-C 2 . The C 1 -(hetero atom) of SK&F 107260 and RGD was 7.7 Å while the C 1 -(hetero atom) of 7a and 17e was 8.2 Å. Overlay of these compounds showed that the carbonyl group of the 4-amidinophenylcarbonyl unit present in most antagonists does not overlap with the arginine carbonyl group of cyclic peptide SK&F 107260. The distance between the Arg-guanidino group and the Asp-carboxylic group was about 14 Å, according to the superimposed stable conformations of SK&F 107260 and other non-peptide antagonists. The carbonyl oxygen of the 5-amidinobenzofuran-2-ylcarbonyl unit is not capable of accessing the same space as the 4-amidinobiphenylcarbonyl unit in BIBU-52 or the 4-amidinophenylaminocarbonyl unit in SB207448. However it is capable of accessing the same space as the arginine carbonyl oxygen of SK&F 107260 and RGD peptide. This result shows that the interaction of our compounds was a three point interaction of the RGD-type. Although the mechanism underlying this difference of activity is not clear, we assume that this difference in activity for rabbit platelets may be due to this three point interaction of the RGD-type. 13) Recently, Bernat and co-workers reported that SR121787 also potently inhibits platelet aggregation in rabbit. 21) However, our compounds are one order of magnitude more effective (IC 50 ϭ 0.02-0.07 mM versus 0.8 mM for SR121787) and, hence, will be powerful tools for use in rabbit antithrombotic models.
Our compounds inhibited human platelet aggregation induced in PRP by ADP, collagen, thrombin, phorbol 12-myristate 13-acetate (PMA) (tumor promoter) and arachidonic acid and the IC 50 values are summarized in Table 10 . Our compounds demonstrated a wide inhibitory spectrum toward major aggregation agonists.
The Fbg receptor of platelets is a member of the integrin superfamily of receptors. Selectivity between Gp IIb/IIIa and other RGD-recognizing integrins is thought to be an impor- tant requirement in order to avoid side-effects. Our compounds were evaluated for their selectivity in inhibiting human umbilical vein endothelial cell (HUVEC) 22) binding to Fbg, vitronectin (VN), fibronectin (FN) and von Willebrand Factor (vWF). The results are presented in Table 11 and show that 17e and 17f was Ͼ2-3 orders of magnitude more effective in inhibiting platelet aggregation than HUVEC binding.
The effects following oral administration of the compounds were evaluated by measuring ex vivo inhibition of platelet aggregation. 23) Results for 17e and 17f in conscious guinea pigs are shown in Fig. 3 . Oral administration of 10 mg/kg of either 17e and 17f to guinea pigs, resulted in a 60% inhibition of ex vivo platelet aggregation after 5 h. In the guinea pig study, 17f possessed a good profile with a long duration of action and high potency. The contrasting oral activities of 17e and 17f in dogs are shown in Figs. 4 and 5. After oral administration, 17e produced more than 50% inhibition at 5 h with a return to baseline after 24 h. However, 17f had no significant ex vivo activity. This study demonstrated that 17f has reduced oral potency in dogs.
We next examined the effect of ester prodrugs of several compounds in terms of increased absorption and longer duration of action. Oral administration of prodrug 18e (10 mg/kg) resulted in 80% inhibition of platelet aggregation in dogs for 6 h after oral administration with a return to baseline after 24 h; 18f produced 80% inhibition for 5 h after oral administration. 18e showed good profiles in dogs, with a duration of action of over 24 h after p.o. administration at 10 mg/kg. The prodrugs exhibited better oral potency (bioavailabilityϭ15-18%), suggesting an improved duration of action. From these results, 18e inhibited platelet aggregation not only in the in vitro assay, but also in the ex vivo assay.
In conclusion, we have described the design and synthesis of novel Fbg receptor antagonists. The results of structureactivity studies allowed modifications which improved the affinity for Fbg receptors. 17e, 17f, and a number of compounds with a cyclohexane moiety have even better in vitro activity. These compounds are highly selective compared with other RGD-recognizing integrins and exhibit a wide- ranging potent inhibition of major aggregation agonists. The corresponding prodrug 18e exhibited potent Fbg receptor antagonism and a long duration of action after oral administration. 18e (AR0510) was selected as a suitable clinical candidate for development as an orally active antithrombotic agent.
Experimental
Chemistry Reagents were purchased from commercial suppliers and used without further purification. Reaction solvents were distilled from an appropriate drying agent before use. Melting points were measured on a Yanaco micromelting point apparatus and are uncorrected. IR and NMR spectra, which were in agreement with the structures cited, were recorded on a Shimadzu IR-420 instrument for IR and a Brucker AM-500 spectrometer Purity of selected final compounds was determined by HPLC using a Inertsil ODS-3 column (4.6 i.d.ϫ250 mm, 5 mm, GL Sciences Inc.): flow rate, 1 ml/min; temperature, 40°C; sample size, 2 mg/ml; injection volume, 1 ml; detection, 270 nm; mobile phase A, 20% MeCN/0.05% TFA in water; mobile phase B, 12% MeCN/0.05% TFA in water (flow rate, 1 ml/min); mobile phase C, 33% MeOH/0.05% TFA in water; mobile phase D, 28% MeOH/0.05% TFA in water (flow rate, 0.75 ml/min). (Although the purity of 2, 7d, 17e, 17m, 29d, 30f, and 31f was verified by NMR and HPLC analyses, their hygroscopic nature prevented satisfactory elemental analyses being obtained. Compounds were, therefore, judged pure by observation of a single peak (Ͼ96%) using two different RP-HPLC methods).
Echistatin was purchased from Bachem (Bubendorf, Switzerland). SC-54701, Ro43-8857 and BIBU-52 were prepared according to a procedure described by Zablocki, 7a) Graul, 7b) Alig 6) and Austel 9) . tert-Butyl 4-(5-Cyanobenzofuran-2-carboxamido)phenoxyacetate (5a). (Standard Procedure A) 3a 14) (300 mg, 1.60 mmol) and 4 (395 mg, 0.008 Ro43-8857 6) 0.07 BIBU-52 9) 0.03 Echistatin 17) 0.017 RGDS 60 a) SC-54701, Ro43-5587 and BIBU-52 were prepared according to the methods reported in the literature and patents. b) Values are expressed as the average of at least two experiments. Table 8 8 Hz) .
tert-Butyl 4-(5-Amidinobenzofuran-2-carboxamido)phenoxyacetate (6a). (Standard Procedure B) 5a (430 mg, 1.10 mmol) was dissolved in a mixed solution of pyridine (30 ml) and Et 3 N (TEA) (7 ml), and hydrogen sulfide gas was bubbled through it for 10 min at room temperature, followed by stirring for 18 h. 17) Low boiling material was distilled from the reaction mixture under reduced pressure and the residue was dissolved in EtOAc. The mixture was washed with 2 N aqueous potassium hydrogensulfate solution, water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure to give the corresponding thioamide as a yellow solid. The thioamide was dissolved in acetone (50 ml, methyl iodide (2 ml) was added and the mixture was refluxed under heating for 40 min. Low boiling material was distilled from the reaction mixture under reduced pressure to give the corresponding thioiminomethyl ester as a yellow solid. Then, MeOH (30 ml) and ammonium acetate (280 mg, 3.64 mmol) were added and the mixture was refluxed under heating for 3 h. Low boiling material was distilled from the reaction mixture under reduced pressure and the residue was purified by silica gel column chromatography (CHCl 3 /MeOH) to give 596 mg of the hydriodide of 6a as a yellow solid (quantitatively in 3 steps).: IR (KBr) cm 4-(5-Amidinobenzofuran-2-carboxamido)phenoxyacetic Acid (7a). (Standard Procedure C) CH 2 Cl 2 (25 ml) was added to the hydriodide (537 mg, 1.00 mmol) of 6a, followed by TFA (8 ml) then stirring at room temperature for 2 h. Et 2 O (100 ml) was added to the reaction mixture and the mixture was stirred for 10 min. The resulting precipitate was collected by filtration and washed with diethyl ether to give 380 mg of the hydriodide of 7a as a pale-brown solid (79% Ethyl 6-[(1-Ethoxy)iminomethyl)]benzofuran-2-carboxylate (10) Ethanol (15 ml) was added to ethyl 6-cyano-2-benzofurancarboxylate 8 14) (135 mg, 0.628 mg) and the mixture was ice-cooled. Hydrogen chloride gas was bubbled through it for 15 min and the mixture was stirred at room temperature for 14 h. Low boiling material was distilled from the reaction mixture under reduced pressure and the residue was dissolved in chloroform. A saturated aqueous sodium hydrogencarbonate solution was added and the mixture was stirred for 10 min. The organic layer was partitioned, washed with water and saturated brine, and dried over anhydrous 6-Cyano-1H-indole-2-carboxylic Acid (3c) Compound 3c was prepared from 8c 15) in a single step according to the procedure for the praparation of 3g (59%): IR (KBr) cm Ϫ1 : 3700-2700, 2250, 1700, 1520. Ͼ100 Ͼ100 Ͼ100 Ͼ100 Ro43-8857 6) Ͼ100 Ͼ100 Ͼ100 Ͼ100 BIBU-52 9) Ͼ100 Ͼ100 Ͼ100 Ͼ100 6-Cyano-1-methylindole-2-carboxylic Acid (3d) To a stirred suspension of NaH (60% in oil, 41.0 mg, 1.03 mmol) in dry DMF (5 ml) was added 8d (200 mg, 0.93 mmol) portionwise at 0°C over 20 min, and then methyliodide (0.062 ml, 1.00 mmol) was added. The mixture was stirred at room temperature for 2 h, and poured into aqueous NH 4 Cl. The precipitate was collected by filtration and washed with water and EtOH to give 85 mg (40%) of 3d as a yellow solid. Compound 3d was prepared from 8d in a single step according to the procedure for the preparation of 3e (70%):
1 H-NMR (DMSO-d 6 In the same manner as in standard procedure B, the cyano group of 5e (850 mg, 2.08 mmol) was converted to an amidino group to give 469 mg of the hydriodide of 6e as a yellow solid (41% in 3 steps): IR (KBr) cm In the same manner as in standard procedure C, the hydriodide (459 mg, 0.830 mmol) of 6e was treated with TFA (7 ml) to give 338 mg of the hydrio- (1H, br s) .
In the same manner as in standard procedure B, the cyano group of 5f (475 mg, 1.22 mmol) was converted to an amidino group to give 462 mg of the hydriodide of 6f as a yellow solid (68% in 3 steps .60 mmol) in EtOH (30 ml) was hydrogenated over 10% palladium on carbon (80 mg) under atmospheric pressure at room temperature for 15 h. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The residue (711 mg, 96%) was used in the next step. To a cooled (3°C) mixture of ethyl 5-aminofuro[2,3-b]pyridine-2-carboxylate (700 mg, 3.40 mmol) in water (21 ml) and THF (10 ml), 12 N HCl (3.1 ml) was added over 5 min. After stirring the mixture for 10 min, sodium nitrite (265 mg, 3.85 mmol) in water (10 ml) was added dropwise for 15 min to maintain the temperature of the solution at 2-3°C. Stirring was continued for another 20 min, then sodium carbonate in water was added to adjust the pH of the solution to about 6. The solution obtained was added dropwise over 10 min at 3°C to a solution of potassium dicyanocuprate prepared from a mixture of cuprous cyanide (623 mg, 6.97 mmol) and potassium cyanide (1.31 g, 13.9 mmol) in water (20 ml). The mixture was left for 1.5 h at 3°C and then heated to 50°C for 2 h. After being cooled to room temperature, the mixture was poured into water and extracted with EtOAc. The extract was washed with water and brine and dried over anhydrous MgSO 4 . After evaporation of the solvent, the residue was purified by silica gel column chromatography (hexane/EtOAc) to give 163 mg of 8g as a yellow solid (20%): IR (KBr) cm Ϫ1 : 2200, 1720, 1290. In the same manner as in standard procedure B, the cyano group of 5g (430 mg, 1.10 mmol) was converted to an amidino group to give 35 mg of the hydriodide of 6g as a yellow solid (11% in 3 steps):
1 H-NMR (DMSOd 6 In the same manner as in standard procedure C, the hydriodide (28 mg, 0.068 mmol) of 6g was treated with TFA (0.5 ml) to give 22 mg of the hydriodide of 7g as a yellow solid (56%): mp: Ͼ250°C (dec. 00 (1H, m), 8.23 (1H, s) .
In the same manner as in standard procedure B, the cyano group of 5h (550 mg, 1.35 mmol) was converted to an amidino group, followed by purification by silica gel column chromatography (CHCl 3 /MeOH) to give 520 mg of the hydriodide of 6h as a pale-brown solid (70% in 3 steps):
1 H-NMR (DMSO-d 6 
4-(5-Amidino-3-methylbenzofuran-2-carboxamido)phenoxyacetatic Acid (7h) In the same manner as in standard procedure C, the hydriodide (510 mg, 0.925 mmol) of 6h was treated with TFA (6 ml) to give 382 mg of hydroiodide of 7h as a brown solid (83%): mp: 220-228°C (dec. tert-Butyl 4-(Methylamino)phenoxyacetate (12a) tert-Butyl 4-aminophenoxyacetate (7.00 g, 31.4 mmol) and succinimide (3.11 g, 31.4 mmol) were added to EtOH (40 ml), followed by a 37% aqueous formaldehyde solution (2.55 g, 31.4 mmol). The mixture was refluxed under heating for 4 h. Low boiling material was distilled from the reaction mixture under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc) to give 8.37 g of tert-butyl 4-(succinimidomethylamino)phenoxyacetate as a yellow solid (84%). This solid (8.30 g, 26.0 mmol) was dissolved in DMSO (50 ml) and sodium borohydride (989 mg, 26.0 mmol) was added, followed by stirring at 100°C for 30 min. After cooling, water was poured into the reaction mixture which was then extracted with Et 2 O. The extract was washed with water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure and the residue was purified by silica gel column chromatography (n-hexane/EtOAc) to give 3.62 g of 3a as a yellow oil (59%): In the same manner as standard procedure B, the cyano group of 13a (652 mg, 1.60 mmol) was converted to an amidino group and purified by silica gel column chromatography (CHCl 3 /MeOH) to give 392 mg of 16a as a yellow solid (44% in 3 steps):
1 H-NMR (DMSO-d 6 Methyl 3-(4-Aminophenyl)propionate (12c) 4-Aminocinnamic acid (15.0 g, 77.6 mmol) was added to a mixed solvent of MeOH (250 ml) and CHCl 3 (150 ml); sulfuric acid (3 ml) was then added, followed by refluxing under heating for 47 h. The reaction mixture was concentrated under reduced pressure, the residue was made weakly alkaline with saturated aqueous sodium hydrogencarbonate, and the mixture was extracted with EtOAc. The extract was washed with water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure to give 7.84 g of methyl 4-aminocinnamate as a yellow solid (72%). This solid (7.80 g, 44.1 mmol) was dissolved in MeOH (250 ml) and 10% palladium-carbon (780 mg) was added. The mixture was stirred at room temperature for 19 h under a hydrogen atmosphere. The reaction mixture was filtered through Celite and low boiling material was distilled from the filtrate under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane/EtOAc) to give 5. 
3-[4-(5-Amidinobenzofuran-2-carboxamido)phenyl]propionic Acid (17c). (Standard Procedure D)
The above compound (162 mg, 0.329 mmol) was suspended in THF (6 ml) and 1 N NaOH (3.0 ml, 3.0 mmol) was added, followed by stirring at room temperature for 1 h. The reaction mixture was adjusted to pH 2 with 1 N HCl and concentrated under reduced pressure. The resulting precipitate was collected by filtration and washed with water to give 82 mg of 17c as a yellow solid (64%): mp: Ͼ250°C. 
5-(5-Amidinofuro[2,3-b]pyridine-2-carbonylamino)-2-pyridyloxyacetate Acid (17d). (Standard Procedure E)
CHCl 3 (30 ml), EtOH (50 ml), conc. HCl (0.5 ml, 6.0 mmol) and 10% palladium-carbon (40 mg) were added to 20d (254 mg, 0.491 mmol), and the mixture was stirred at room temperature for 14 h under a hydrogen atmosphere. The reaction mixture was filtered and low boiling material was distilled from the filtrate under reduced pressure. The residue was purified by silica gel column chromatography (CHCl 3 /MeOH) to give 230 mg (quantitative) of 16d as a brown solid.
In the same manner as standard procedure D, 16d (220 mg, 0.484 mmol) was hydrolyzed with 1 N NaOH (20 ml, 20 mmol tert-Butyl trans-(4-Aminocyclohexyloxy)acetate (12e) Toluene (200 ml) was added to a mixture of tert-4-aminocyclohexanol (5.00 g, 43.4 mmol), N,N-dimethylurea (3.82 g, 43.4 mmol), 37% formalin (50 ml), N-methylmorpholine (9.54 ml, 86.8 mmol) and dioxane (10 ml), and the mixture was heated for about 5 h while removing water by azeotropic distillation. Low boiling material was distilled from the reaction mixture under reduced pressure, and the residue was purified by silica gel column chromatography (CH 2 were dissolved in toluene (13 ml), and tetra-n-butylammonium hydrogensulfate (45 mg, 0.13 mmol) was added to the mixture. A solution of NaOH (13.2 g, 330 mmol) dissolved in water (13.2 ml) was added dropwise, and the mixture was stirred at room temperature for 15 h. The organic layer was partitioned, washed with water and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure, and the residue was purified by silica gel column chromatography (CH 2 
trans-5-[4-[(tert-Butoxycarbonyl)methyloxy]cyclohexyl]-1,3-dimethyl-
hexahydro-2-oxo-1,3,5-triazine (300 mg, 0.879 mmol) was dissolved in tertbutanol (5 ml) and a saturated aqueous ammonium chloride solution (5 ml) was added, followed by refluxing under heating for 2 h. The reaction mixture was adjusted to pH 10 with 1 N NaOH and extracted with benzene. The extract was washed with water and saturated brine, and dried over anhydrous Na 2 SO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure and the residue was purified by silica gel column chromatography (CH 2 Cl 2 /MeOH) to give 130 mg of 12e as a colorless solid (57%): trans-[4-(5-Amidinobenzofuran-2-carboxamido)cyclohexyloxy]acetic Acid (17e) tert-Butanol (13 ml) and 10% palladium-carbon (20 mg) were added to 20e (135 mg, 0.246 mmol) and the mixture was refluxed with heating for 7 h under a hydrogen atmosphere. The reaction mixture was filtered through Celite and low boiling material was distilled from the filtrate under reduced pressure. TFA (1 ml) was added to the residue and the mixture was stirred at room temperature for 1 h. Et 2 O was then added to the reaction mixture and the resulting precipitate was collected by filtration and washed with Et 2 O to give 103 mg of 17e as a colorless solid (88%): 55 (1H, m), 3.65-3.90 (1H, m), 4.03 (2H, s), 7.71 (1H, s) Ethyl 3-(4-Aminopiperidino)propionate (12g) 4-Piperodinone (10.0 g, 73.7 mmol) and potassium carbonate (30.6 g, 221 mmol) were added to DMF (100 ml), and then ethyl 3-bromopropionate (10.0 ml, 78.0 mmol) was added. The mixture was filtered and the filtrate was added to saturated aqueous sodium hydrogencarbonate (150 ml). The mixture was extracted with EtOAc. The mixture was washed with saturated brine and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure and the residue was purified by silica gel column chromatography (CHCl 3 /MeOH) to give 9.70 g of ethyl 3-(4-oxopiperidino)propionate as a pale-yellow oil (66%).
Then, ethyl 3-(4-oxopiperidino)propionate (1.29 g, 6.47 mmol) and benzylamine (0.85 ml, 7.78 mmol) were dissolved in EtOH (40 ml). A solution of sodium cyanoborohydride (256 mg, 4.22 mmol) dissolved in EtOH (20 ml) was added at room temperature and then acetic acid (1 ml) was added to adjust the pH to 6-7. The mixture was stirred at room temperature for 18 h and conc. HCl (3 ml) added to adjust the pH to 1-2. The resulting precipitate was collected by filtration and saturated aqueous sodium hydrogencarbonate (150 ml) was added to adjust the mixture pH to 8-9. The mixture was extracted with EtOAc, and the extract was washed with saturated brine and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure to give 1.39 g of ethyl 3-(4-benzylaminopiperidino)propionate as a colorless oil (74%). This oil (1.11 g, 3.82 mmol) was dissolved in EtOH (120 ml) and 10% palladium-carbon (320 mg) was added. The mixture was refluxed with heating for 5 h under a hydrogen atmosphere. The reaction mixture was filtered and low boiling material was distilled from the filtrate under reduced pressure to give 617 mg of 12g as a colorless oil (81%): IR (neat) cm
Ϫ1
: 3300, 2900, 1720, 1600. A, 19 (1.08 g, 3.19 mmol) and 12g (610 mg, 3 Ethyl 3-[4-(5-Amidinobenzofuran-2-carboxamido)piperidino]propionate (18g) The 20g (400 mg, 0.768 mmol) was dissolved in EtOH (100 ml) and 10% palladium-carbon (80 mg) was added. The mixture was stirred at room temperature for 4 h under a hydrogen atmosphere. The reaction mixture was filtered and low boiling material was distilled from the filtrate under reduced pressure. The residue was purified by silica gel (NH type) 27 Methyl N-(5-Amidinobenzofuran-2-carbonyl)-4-piperidinyloxyacetate In the same manner as standard procedure A, 3a (185 mg, 0.988 mmol) and tert-butyl 4-piperidinyloxyacetate 12h (255 mg, 1.18 mmol) were condensed and purified by silica gel column chromatography (n-hexane/EtOAc) to give 289 mg of 13h as a colorless solid (76%).
In the same manner as standard procedure F, the cyano group of 13h (280 mg, 0.728 mmol) was converted to an amidino group and purified by silica gel column chromatography (CHCl 3 /MeOH) to give 62 mg of the title compound as a colorless solid (22%): 66 mmol) and potassium carbonate (2.22 g, 16.08 mmol) were added to DMF (100 ml) and tert-butyl bromoacetate (1.57 g, 8.04 mmol) was then added dropwise under ice-cooling. The mixture was stirred for 30 min at room temperature for 30 min. The reaction mixture was filtered and water (200 ml) was added to the filtrate. The mixture was extracted with EtOAc. The extract was washed with water and saturated with brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane/EtOAc) to give 2.98 g of tert-butyl trans-[4-(triphenylmethylamino)cyclohexylamino]acetate as a colorless solid (83%). This solid (2.40 g, 5.10 mmol), 4-dimethylaminopyridine (0.31 g, 2.55 mmol) and pyridine (0.81 g, 10.20 mmol) were dissolved in CH 2 Cl 2 (40 ml) and a solution of di-tert-butyl dicarbonate (1.17 g, 5.35 mmol) dissolved in CH 2 Cl 2 (10 ml) was added dropwise under ice-cooling, which was followed by stirring for 2 h. Water (100 ml) and 1 N HCl (20 ml) were then added and the mixture was extracted with CHCl 3 . The extract was dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane/EtOAc) to give 1.82 g of tert-butyl trans-[4-(triphenylmethylamino)cyclohexyl-N-(tert-butoxycarbonyl)amino]acetate as a colorless solid (63%). This solid (1.82 g, 3. 19 mmol) was dissolved in EtOH (60 ml) and 10% palladium-carbon (0.40 g) was added. The mixture was refluxed with heating for 16 h under a hydrogen atmosphere. The reaction mixture was filtered through Celite and low boiling material was distilled from the filtrate under reduced pressure. Water (20 ml) and 1 N HCl (10 ml) were added to the residue and the mixture was extracted with Et 2 O. Saturated aqueous sodium hydrogencarbonate was added to the aqueous layer to make it alkaline, and the mixture was extracted with CHCl 3 . The extract was dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure to give 0.67 g of 12i as a pale-yellow solid (64%): IR (KBr) cm
: 3400, 2900, 1738, 1690, 1435. 20i (482 mg, 0.743 mmol) was dissolved in EtOH (20 ml) and 10% palladium-carbon (150 mg) was added, followed by refluxing with heating for 16 h under a hydrogen atmosphere. The reaction mixture was filtered through Celite and low boiling material was distilled from the filtrate under reduced pressure. The residue was purified by silica gel (NH type) column chromatography (CHCl 3 /MeOH) to give 328 mg of 16i as a pale-yellow solid (86%): IR (KBr) cm Ϫ1 : 3600-3000, 2920, 1735, 1635, 1590, 1520, 1432. trans-[4-(5-Amidinobenzofuran-2-carboxamido)cyclohexylamino]-acetic Acid (17i) 16i (216 mg, 0.420 mmol) was dissolved in CH 2 Cl 2 (8 ml) and TFA (4 ml) was added. The mixture was stirred at room temperature for 23 h. The reaction mixture was concentrated to about 1/3 under reduced pressure and Et 2 O (50 ml) was added. Di-tert-butyl trans-(4-Aminocyclohexylamino)diacetate (12j) 1,4-Diaminocyclohexane (cis, trans mixture) (24.0 g, 210 mmol) and TEA (16.3 ml, 117 mmol) were dissolved in CH 2 Cl 2 (400 ml). A solution of triphenylmethyl chloride (32.5 g, 117 mmol) dissolved in CH 2 Cl 2 (100 ml) was added dropwise with ice-cooling and the mixture was stirred for 15 min at room temperature for 45 min. The reaction mixture was filtered and low boiling material was distilled from the filtrate under reduced pressure. Water (100 ml) was added to the residue and extracted with CHCl 3 . The extract was dried over anhydrous Na 2 SO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure. The residue was purified by silica gel (NH type) column chromatography (CHCl 3 /MeOH) to give 18.4 g of 1-amino-4-(triphenylmethylamino)cyclohexane as a pale-yellow oil (25%).
1-Amino-4-(triphenylmethylamino)cyclohexane (18.4 g, 51.7 mmol) and potassium carbonate (15.0 g, 108.6 mmol) were added to DMF (250 ml), and tert-butyl bromoacetate (20.7 g, 106.0 mmol) was added dropwise under icecooling, followed by stirring at room temperature for 2.5 h. Thereafter, triethylamine (14.8 ml, 106 mmol) was added and the mixture was stirred for 1.5 h. The reaction mixture was filtered and water (500 ml) was added to the filtrate. The mixture was extracted with EtOAc and the extract was washed with water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane/EtOAc) to give 3.56 g of di-tert-butyl trans- [4-(triphenylmethylamino) cyclohexylamino]-diacetate as a colorless solid (12%) and 16.23 g of di-tert-butyl cis- [4-(triphenylmethylamino) cyclohexylamino]diacetate as a viscous pale-yellow oil (54%). Di-tert-butyl trans- [4-(triphenylmethylamino) cyclohexylamino]-diacetate (3.46 g, 5.92 mmol) was dissolved in MeOH (100 ml) and mixed with 10% palladium-carbon (0.75 g). The mixture was refluxed with heating for 7 h under a hydrogen atmosphere. The reaction mixture was filtered through Celite and low boiling material was distilled from the filtrate under reduced pressure. 1 N HCl (30 ml) and water (50 ml) were added to the residue, the mixture was extracted with CHCl 3 , and the extract was dried over anhydrous Na 2 SO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure to give 2.13 g (quantitative) of 12j as a pale-yellow oil: IR (CHCl 3 ) cm Di-tert-butyl trans-[4-(5-Amidinobenzofuran-2-carboxamido)cyclohexylamino]diacetate (16j) 20j (1.60 g, 2.41 mmol) was dissolved in tert-butanol (100 ml) and 10% palladium-carbon (0.56 g) was added, followed by refluxing with heating for 14 h under a hydrogen atmosphere. The reaction mixture was filtered through Celite and low boiling material was distilled from the filtrate under reduced pressure. The residue was purified by silica gel (NH type) column chromatography (CHCl 3 tert-Butyl trans-(4-Aminocyclohexyl-N-n-butylamino)acetate (12k) trans-1,4-Diaminocyclohexane (12.0 g, 105 mmol) was reacted with triphenylmethyl chloride (14.7 g, 52.5 mmol) to give 11.1 g of trans-1-amino-4-(triphenylmethylamino)cyclohexane as a colorless solid (30%). This solid (2.00 g, 5.61 mmol) and n-butylaldehyde (400 mg, 5.61 mmol) were dissolved in EtOH (70 ml) and a suspension of sodium cyanoborohydride (220 mg, 3.64 mmol) suspended in EtOH (30 ml) was added dropwise. Then, acetic acid (0.6 ml) was added to adjust the pH to 6-7 and the mixture was stirred at room temperature for 14 h. Water (200 ml) was added to the reaction mixture and the mixture was concentrated to 1/3 under reduced pressure. The condensate was extracted with CHCl 3 and the extract was dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure and the residue was purified by silica gel (NH type) column chromatography (n-hexane/CHCl 3 ) to give 1.72 g trans-1-(n-butylamino)-4-(triphenylmethylamino)cyclohexane as a colorless oil (74%). This oil (1.72 g, 4.17 mmol) and potassium carbonate (1.21 g, 8.75 mmol) were added to DMF (80 ml) and tert-butyl bromoacetate (850 mg, 4.38 mmol) was added dropwise at room temperature, followed by stirring for 4.5 h. The reaction mixture was filtered and water (100 ml) was added to the filtrate. The mixture was extracted with EtOAc and the extract was washed with water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure and the residue was purified by silica gel column chromatography (n-hexane/EtOAc) to give 1.88 g of tert-butyl trans- [4-(triphenylmethylamino) cyclohexyl-N-n-butylamino]acetate as a colorless oil (86%). This oil (1.74 g, 3.31 mmol) was dissolved in EtOH (60 ml) and 10% palladium-carbon (520 mg) was added. The mixture was refluxed under heating for 4 h under a hydrogen atmosphere. The reaction mixture was filtered through Celite and low boiling material was distilled from the filtrate under reduced pressure. Water (30 ml) and 1 N HCl (10 ml) were added to the residue and the mixture was extracted with Et 2 O. Sodium hydrogencarbonate was added to the aqueous layer to make it alkaline and the mixture was extracted with CHCl 3 . The extract was dried over anhydrous Na 2 In the same manner as standard procedure E, 20k (941 mg, 1.56 mmol) was subjected to hydrogen reduction and purified by silica gel (NH type) column chromatography (CHCl 3 /MeOH) to give 625 mg of 16k as a paleyellow solid (85%): IR (KBr) cm
: 3600-3000, 2900, 1720, 1635, 1520, 1450. 59 mmol) was dissolved in EtOH (100 ml) and the solution was ice-cooled. HCl gas was bubbled through it for 20 min, followed by stirring for 18 h. Low boiling material was distilled from the reaction mixture under reduced pressure, and the residue obtained and EtOH (100 ml) were ice-cooled. NH 3 gas was bubbled through it for 20 min, and the mixture was refluxed with heating for 3 h. Low boiling material was distilled from the reaction mixture under reduced pressure, and the residue was purified by silica gel column chromatography (CHCl 3 /MeOH) to give 3.10 g of 16l as a pale-brown solid (82% in 2 steps): IR (KBr) cm
: 3250, 2900, 1720, 1640, 1600, 1110. 5-Cyano-3-methoxybenzofuran-2-carboxylic Acid (3i) Methyl 5-bromo-2-hydroxybenzoate (25.6 g, 129 mmol), copper(I) cyanide (20.8 g, 257 mmol) and copper sulfate (200 mg) were added to N-methyl-2-pyrrolidone (250 ml) and the mixture was refluxed under heating for 2 h under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and poured into a mixture of water (500 ml) and ethylenediamine (10 ml). After filtration, the filtrate was extracted with EtOAc. The extract was washed with water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc/n-hexane) to give 3.35 g of methyl 5-cyano-2-hydroxybenzoate as a colorless solid (15%). This solid (3.35 g, 18.9 mmol) and potassium carbonate (5.23 g, 37.0 mmol) were added to DMF (45 ml), and ethyl bromoacetate (2.21 ml, 19.9 mmol) was gradually added, followed by stirring at room temperature for 18 h. Water was added to the reaction mixture and the mixture was extracted with an equal mixture of EtOAc and nhexane. The extract was washed with water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure to give a crude product, ethyl 4-cyano-2-methoxycarbonylphenoxyacetate. This product (3.39 g, 19.3 mmol) was dissolved in EtOH (20 ml) and the obtained solution was gradually added to a solution of metallic sodium (622 mg, 27.1 mmol) dissolved in ethanol (50 ml). The mixture was stirred at room temperature for 45 min. Low boiling material was distilled from the reaction mixture under reduced pressure and water (200 ml) was added to the residue. Dilute HCl was added to adjust the pH to 2-3. The resulting precipitate was collected by filtration to give 2.98 g (quantitative) of ethyl 5-cyano-3-hydroxybenzofuran-2-carboxylate as a colorless solid: IR (KBr) cm Ethyl 5-cyano-3-hydroxybenzofuran-2-carboxylate (200 mg, 0.866 mmol), DMSO (131 mg, 1.04 mmol) and potassium carbonate (132 mg, 0.953 mmol) were added to acetone (140 ml), and the mixture was refluxed under heating for 1.5 h. Low boiling material was distilled from the reaction mixture under reduced pressure and water (200 ml) was added to the residue, which was followed by extraction with EtOAc. The extract was washed with water and saturated brine, and dried over anhydrous MgSO 4 . After filtration, low boiling material was distilled from the filtrate under reduced pressure to give 193 mg of ethyl 5-cyano-3-methoxybenzofuran-2-carboxylate (91%). The compound (170 mg, 0.694 mmol) obtained was dissolved in MeOH (5 ml) and potassium hydroxide (160 mg, 2.86 mmol) was added, followed by refluxing under heating for 45 min. Low boiling material was distilled from the reaction mixture under reduced pressure and 1 N HCl was added to the residue to adjust the pH to 2-3. The resulting precipitate was collected by filtration to give 123 mg of 3i as a colorless solid (82%): IR (KBr) cm In the same manner as standard procedure B, the cyano group of 13m (310 mg, 0.724 mmol) was converted to an amidino group and purified by silica gel (NH type) column chromatography (CHCl 3 /MeOH) to give 185 mg of 16m as a colorless solid (57%): IR (KBr) cm : 1720, 1640,
19)
PRP was prepared from the blood taken from healthy volunteers by centrifugation in the presence of 0.38% sodium citrate, and used for the determination.
Two minutes after the test compounds were added to the above PRP, ADP (1-5 mM) was added, at a concentration such that primary aggregation alone was observed. The suppression of ADP aggregation by the compounds was evaluated. The percentage suppression was determined by varying the concentration of the compounds and the concentration of the compound at which the aggregation was suppressed by 50% (IC 50 ) was calculated; this was taken as the activity of the compound. Throughout the platelet aggregation assay, Ro43-8857 was used as a reference compound, and we confirmed that the IC 50 values of this compound varied significantly with PRPs from different blood donors (85 nMϮ33; meanϮS.E.M. from three different donors/each assay, nϭ62). Then 1 mM to 10 mM ADP was added to induce platelet aggregation in order to maintain 85 nMϮ13 for the IC 50 value of this compound. We confirmed that the number of platelets in PRP was within the normal range (2-4ϫ10 5 /ml) before the start of each platelet aggregation assay. We used the PRP without matching the platelet numbers. The concentration of ADP (1.25-2.5 mM) was chosen each time to give a similar range to the first aggregation (30-50% aggregation in the aggregometer used). For each compound, at least three assays were performed with PRPs from different donors to calculate the IC 50 value. We used Ro43-8857 as a reference compound in each assay in order to check the reproducibility, and believe that the assay is reliable enough (85 nMϮ2.5; meanϮS.E.M. from three different donors/each assay, nϭ62).
In Table 8 , we used PRPs or WPSs (washed platelet suspension) from beagle dogs (Keari, Osaka, Japan), male Hartley guinea-pigs (Keari, Osaka, Japan), Japanese white rabbits (Keari, Osaka, Japan), and Wistar rats (Keari, Osaka, Japan) instead of humans.
In Table 10 , we used collagen (1 mg/ml, Sigma Chemical., U.S.A.), thrombin (0.1 u/ml, from human plasma, Sigma Chemical., U.S.A.), PMA (0.5 mM, Funakoshi, Japan), and arachidonic acid (5 mM, free type, Sigma Chemical., U.S.A.) instead of the above ADP.
Anti-protease Activity
22)
The serine protease-inhibition actions of GP IIb/IIIa antagonists were assessed using human a-thrombin, human plasmin, human blood coagulation factor Xa and bovine b-trypsin. Briefly, 10 nM protease was mixed with 10 Ϫ4 M GP IIb/IIIa antagonist or DMSO in Tris-HCl buffered saline for 10 min at room temperature. Protease activity was measured following the addition of 2 mM at the respective synthetic substrate by monitoring the absorption at 405 nm at 25°C on a DV-7400 Spectrophotometer (Beckman). The synthetic substrates used were S-2303 for thrombin, S-2238 for FXa and S-2251 for plasmin and b-trypsin. The Ki app value was obtained by plotting the percentage inhibition against the inhibitor concentrations. Values are the average of at least two determinations. Nafamostat mesylate (Futhan) was used as a respective protease inhibitor. well and incubated for 2 h at 37°C in the presence of various concentrations of the test compound. After being washed with PBS, the adherent cells were stained with 0.2% crystal violet solution (10% EtOHϩ2.8% formalin). The dye was solubilized by the addition of 50% EtOH (in 10 mM Tris-HCl, pH7.4) and the number of adherent cells was quantified by reading the absorbance at 590 nm. Nonspecific adhesion was assessed by the adhesion of cells to BSA-coated wells. Values are the average of at least two determinations.
